The Motley Fool

Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?

Vertex's cystic fibrosis portfolio has been a raging success for the company. The biotech’s next potential product addresses the extremely common problem of pain -- and could become its next ...
Seeking Alpha

V2X, INC. ANNOUNCES SALE OF 2.25 MILLION SHARES OF COMMON STOCK IN SECONDARY OFFERING BY VERTEX AEROSPACE

RESTON, Va., Nov. 12, 2025 /PRNewswire/ -- V2X, Inc. (VVX) ("V2X"), a leading provider of global mission solutions, announced today the sale of 2.25 million shares of its common stock on an ...
Nasdaq

Vertex Announces Pricing of Public Offering of Class A Common Stock by Selling Stockholder

KING OF PRUSSIA, Pa., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, announced today the pricing of an ...
The Motley Fool

This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment, and that business generates billions of dollars in annual revenue. The biotech has treatment candidate in another indication ...